Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein (Q35113667)

6 August 2017

1 reference

title

Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein (English)

1 reference

6 August 2017

Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein (English)

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

main subject

multiple drug resistance

1 reference

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

Hilary Thomas

1 reference

6 August 2017

Helen M. Coley

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12712010

27 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12712010

27 December 2023

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

159-165

1 reference

Multidrug resistance in cancer: role of ATP-dependent transporters

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

The P-glycoprotein multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Clinical trials of P-glycoprotein reversal in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

ABC transporters as phenotypic markers and functional regulators of stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Development of multidrug-resistance convertors: sense or nonsense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000207

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro

27 December 2023

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP

27 December 2023

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

27 December 2023

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

3944

Wandel C.

1999

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

749

Mistry P.

2001

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

4171

Dantzig A.H.

1996

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

27 December 2023

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein

27 December 2023

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

2964

Newman M.J.

2000

1 reference

https://api.crossref.org/works/10.1177/107327480301000207

27 December 2023

Identifiers

0 references

1 reference